Otsuka Corporation

4768

JP3188200004

IT Services & Consulting

Market Closed - Japan Exchange Other stock markets 06:30:00 09/02/2026 GMT			5-day change	1st Jan Change
3,017.00 ^JPY	+0.17%		-1.37%	-6.65%

02-04	Biodexa announces exclusive license of Otsuka's OPB-171775, a potent phase 1 ready molecular glue for GIST	RE
02-04	HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI

Otsuka Profit Increases 27% in H1

Published on 08/01/2025 at 01:06 pm BST

MT Newswires

Latest news about Otsuka Corporation

02-04	Biodexa announces exclusive license of Otsuka's OPB-171775, a potent phase 1 ready molecular glue for GIST	RE
02-04	HBM Holdings Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI
02-02	Otsuka Corporation Announces Dividend for the Fiscal Year Ended December 31, 2025, Payable on March 30, 2026	CI
02-02	Otsuka Corporation Provides Consolidated Earnings Guidance for the Six Months Ending June 30, 2026 and Fiscal Year Ending March 31, 2026	CI
02-02	Otsuka Corporation Provides Dividend Guidance for the Second Quarter End of Fiscal Year Ending March 31, 2026	CI
02-02	Otsuka Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2026	CI
02-02	Otsuka Corporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-22	Vertex Pharmaceuticals Poised for Higher Valuation on Povetacicept, Cystic Fibrosis Pipeline, RBC Says	MT
01-12	Ionis Pharmaceuticals, Inc. Provides Additional Updates on Key Milestones Expected in 2026	CI
11-25	US FDA approves Otsuka's drug for a type of kidney disease	RE
11-07	New purchases in Asia portfolio
31/10/25	Otsuka Corporation Provides Year End Dividend Guidance for the Fiscal Year Ending December 31, 2025	CI
31/10/25	Otsuka Corp Nine-Month Profit Up 27%	MT
10/10/25	Otsuka Corporation has positive outlook and boosts guidance
20/09/25	Otsuka and Lundbeck receive complete response letter from U.S. FDA for sNDA of Rexulti (brexpiprazole) in combination with sertraline for the treatment of adults with PTSD	RE
20/09/25	Otsuka and Lundbeck Receives Complete Response Letter from U.S. FDA for sNDA of REXULTI®? (Brexpiprazole) in Combination with Sertraline for the Treatment of Adults with PTSD	CI
14/09/25	Fangzhou launches "Xingshi" LLM, says in Innovent, Otsuka tie-up	RE
19/08/25	Cantargia Appoints Hilde Steineger as New CEO	FW
01/08/25	Otsuka Profit Increases 27% in H1	MT
01/08/25	Otsuka Corporation Revises Consolidated Earnings Guidance for the Full Year Ending December 31, 2025	CI
01/08/25	Otsuka Corporation Announces Dividend for the Second Quarter Ended June 30, 2025, Payable on September 3, 2025	CI
21/07/25	US FDA advisers recommend against Otsuka, Lundbeck's PTSD combination treatment	RE
21/07/25	FDA Panel Rejects Efficacy of Rexulti for PTSD Treatment	FW
21/07/25	Lundbeck, Otsuka's PTSD Treatment Combination Fails to Win US FDA Committee Recommendation	MT
18/07/25	US FDA advisers recommend against Otsuka's PTSD combination treatment	RE

OTSUKA CORPORATION is a Japan-based company mainly engaged in the sale of system equipment, the installation support and maintenance services. The Company operates through two business segments. System Integration segment conducts consulting, hardware and software sales, contract software development, equipment installation and network construction. Service & Support segment provides office supply, maintenance services, as well as business support services. The Company is also involved in the car maintenance business and insurance business.

Employees

9,680

Sector

IT Services & Consulting

Calendar

03-26 - Annual General Meeting

More about the company